Brief: Celyad Oncology Announces Dosing Of First Patient In Phase 1 Immunicy-1 Trial Of Cyad-211
04/12/2020 06:03
Dec 4 (Reuters) - CELYAD ONCOLOGY CYAD.BR :
* CELYAD ONCOLOGY ANNOUNCES DOSING OF FIRST PATIENT IN PHASE
1
IMMUNICY-1 TRIAL OF CYAD-211 FOR MULTIPLE MYELOMA
* PRELIMINARY DATA FROM PHASE 1 TRIAL ARE EXPECTED FIRST
HALF 2021
* ADDITIONAL EUR 3.4 MILLION IN NON-DILUTIVE FUNDING FROM
SPW-RECHERCHE OF WALLOON REGION TO SUPPORT ADVANCEMENT OF
CYAD-211
* CONFIRMS ITS PREVIOUS GUIDANCE THAT ITS EXISTING TREASURY
POSITION SHOULD BE SUFFICIENT, BASED ON CURRENT SCOPE OF
ACTIVITIES, TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE
REQUIREMENTS INTO Q3 OF 2021
* ENROLLMENT IN IMMUNICY-1 TRIAL WILL CONTINUE OVER COMING
MONTHS
AND WE EXPECT TO REPORT PROOF-OF-CONCEPT DATA FROM INITIAL DOSE
COHORTS OF TRIAL DURING H1 2021
Source text for Eikon: ID:nGNXbX43dF
Further company coverage: CYAD.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587785110;))